Audit of performance of needle core biopsy diagnoses of screen detected breast lesions

Maysa E. El-Sayed, Emad A. Rakha, Jacquie Reed, Andrew H. S. Lee, Andrew J. Evans, Ian O. Ellis

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    Breast needle core biopsy (NCB) is now a standard diagnostic procedure in the triple assessment of screen detected breast lesions. Therefore, it is important to provide robust and up-to-date data on the performance of NCB in the screening setting. However, previous studies of NCB have suffered from either limitation in the number of assessed cases or included a mix of symptomatic and screen detected breast lesions. in this study, we have evaluated the performance of a large series of uniformly assessed NCBs of screen detected lesions (20001 cases) over a period of 10 years (1997-2007). our results showed a gradual increase in the number of NCBs and an improvement of their performance over the period of the study; absolute sensitivity increased from 84.9% to 96,4% and complete sensitivity increased from 90.9% to 99.7%. There was also a gradual reduction in the number of surgical interventions after benign (B2) and negative (B1) NCB diagnoses. Our study provides data showing variance from the suggested thresholds for the measures of performance of NCB in the United Kingdom which could be used to provide updated evidence-based thresholds for assessment of performance of NCB diagnosis use in the assessment of breast cancer screen detected lesions in the UK and elsewhere. (C) 2008 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)2580-2586
    Number of pages7
    JournalEuropean Journal of Cancer
    Volume44
    Issue number17
    DOIs
    Publication statusPublished - Nov 2008

    Keywords

    • Screen detected breast lesions
    • Needle core biopsy
    • Quality assurance
    • PREOPERATIVE DIAGNOSIS
    • ASPIRATION-CYTOLOGY
    • CANCER
    • UNDERESTIMATION
    • SPECIMENS
    • ACCURACY
    • PROGRAM

    Cite this

    El-Sayed, Maysa E. ; Rakha, Emad A. ; Reed, Jacquie ; Lee, Andrew H. S. ; Evans, Andrew J. ; Ellis, Ian O. / Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. In: European Journal of Cancer. 2008 ; Vol. 44, No. 17. pp. 2580-2586.
    @article{2f097549d41f431382b30db471a2ead6,
    title = "Audit of performance of needle core biopsy diagnoses of screen detected breast lesions",
    abstract = "Breast needle core biopsy (NCB) is now a standard diagnostic procedure in the triple assessment of screen detected breast lesions. Therefore, it is important to provide robust and up-to-date data on the performance of NCB in the screening setting. However, previous studies of NCB have suffered from either limitation in the number of assessed cases or included a mix of symptomatic and screen detected breast lesions. in this study, we have evaluated the performance of a large series of uniformly assessed NCBs of screen detected lesions (20001 cases) over a period of 10 years (1997-2007). our results showed a gradual increase in the number of NCBs and an improvement of their performance over the period of the study; absolute sensitivity increased from 84.9{\%} to 96,4{\%} and complete sensitivity increased from 90.9{\%} to 99.7{\%}. There was also a gradual reduction in the number of surgical interventions after benign (B2) and negative (B1) NCB diagnoses. Our study provides data showing variance from the suggested thresholds for the measures of performance of NCB in the United Kingdom which could be used to provide updated evidence-based thresholds for assessment of performance of NCB diagnosis use in the assessment of breast cancer screen detected lesions in the UK and elsewhere. (C) 2008 Elsevier Ltd. All rights reserved.",
    keywords = "Screen detected breast lesions, Needle core biopsy, Quality assurance, PREOPERATIVE DIAGNOSIS, ASPIRATION-CYTOLOGY, CANCER, UNDERESTIMATION, SPECIMENS, ACCURACY, PROGRAM",
    author = "El-Sayed, {Maysa E.} and Rakha, {Emad A.} and Jacquie Reed and Lee, {Andrew H. S.} and Evans, {Andrew J.} and Ellis, {Ian O.}",
    year = "2008",
    month = "11",
    doi = "10.1016/j.ejca.2008.05.024",
    language = "English",
    volume = "44",
    pages = "2580--2586",
    journal = "European Journal of Cancer",
    issn = "0959-8049",
    publisher = "Elsevier Ltd",
    number = "17",

    }

    Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. / El-Sayed, Maysa E.; Rakha, Emad A.; Reed, Jacquie; Lee, Andrew H. S.; Evans, Andrew J.; Ellis, Ian O.

    In: European Journal of Cancer, Vol. 44, No. 17, 11.2008, p. 2580-2586.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Audit of performance of needle core biopsy diagnoses of screen detected breast lesions

    AU - El-Sayed, Maysa E.

    AU - Rakha, Emad A.

    AU - Reed, Jacquie

    AU - Lee, Andrew H. S.

    AU - Evans, Andrew J.

    AU - Ellis, Ian O.

    PY - 2008/11

    Y1 - 2008/11

    N2 - Breast needle core biopsy (NCB) is now a standard diagnostic procedure in the triple assessment of screen detected breast lesions. Therefore, it is important to provide robust and up-to-date data on the performance of NCB in the screening setting. However, previous studies of NCB have suffered from either limitation in the number of assessed cases or included a mix of symptomatic and screen detected breast lesions. in this study, we have evaluated the performance of a large series of uniformly assessed NCBs of screen detected lesions (20001 cases) over a period of 10 years (1997-2007). our results showed a gradual increase in the number of NCBs and an improvement of their performance over the period of the study; absolute sensitivity increased from 84.9% to 96,4% and complete sensitivity increased from 90.9% to 99.7%. There was also a gradual reduction in the number of surgical interventions after benign (B2) and negative (B1) NCB diagnoses. Our study provides data showing variance from the suggested thresholds for the measures of performance of NCB in the United Kingdom which could be used to provide updated evidence-based thresholds for assessment of performance of NCB diagnosis use in the assessment of breast cancer screen detected lesions in the UK and elsewhere. (C) 2008 Elsevier Ltd. All rights reserved.

    AB - Breast needle core biopsy (NCB) is now a standard diagnostic procedure in the triple assessment of screen detected breast lesions. Therefore, it is important to provide robust and up-to-date data on the performance of NCB in the screening setting. However, previous studies of NCB have suffered from either limitation in the number of assessed cases or included a mix of symptomatic and screen detected breast lesions. in this study, we have evaluated the performance of a large series of uniformly assessed NCBs of screen detected lesions (20001 cases) over a period of 10 years (1997-2007). our results showed a gradual increase in the number of NCBs and an improvement of their performance over the period of the study; absolute sensitivity increased from 84.9% to 96,4% and complete sensitivity increased from 90.9% to 99.7%. There was also a gradual reduction in the number of surgical interventions after benign (B2) and negative (B1) NCB diagnoses. Our study provides data showing variance from the suggested thresholds for the measures of performance of NCB in the United Kingdom which could be used to provide updated evidence-based thresholds for assessment of performance of NCB diagnosis use in the assessment of breast cancer screen detected lesions in the UK and elsewhere. (C) 2008 Elsevier Ltd. All rights reserved.

    KW - Screen detected breast lesions

    KW - Needle core biopsy

    KW - Quality assurance

    KW - PREOPERATIVE DIAGNOSIS

    KW - ASPIRATION-CYTOLOGY

    KW - CANCER

    KW - UNDERESTIMATION

    KW - SPECIMENS

    KW - ACCURACY

    KW - PROGRAM

    U2 - 10.1016/j.ejca.2008.05.024

    DO - 10.1016/j.ejca.2008.05.024

    M3 - Article

    VL - 44

    SP - 2580

    EP - 2586

    JO - European Journal of Cancer

    JF - European Journal of Cancer

    SN - 0959-8049

    IS - 17

    ER -